Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
Triana Biomedicines, Inc. See All Filings	D	2025-12-04 09:54:03 UTC
Amount To Be Raised $120,061,960 Associated Brokers / Dealers N/A CIK Number 0001815337 Filed Document 0001815337-25-000003 Exclusions or Exemptions 506b Accepted Date 2025-12-04 09:54:03 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Triana Biomedicines, Inc. See All Filings	D/A	2022-04-19 13:07:06 UTC
Amount To Be Raised $85,100,014 Associated Brokers / Dealers N/A CIK Number 0001815337 Filed Document 0001815337-22-000004 Exclusions or Exemptions 506b Accepted Date 2022-04-19 13:07:06 UTC Type of Offering D/A Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Triana Biomedicines, Inc. See All Filings	D	2022-02-11 16:21:25 UTC
Amount To Be Raised $80,000,016 Associated Brokers / Dealers N/A CIK Number 0001815337 Filed Document 0001815337-22-000002 Exclusions or Exemptions 506b Accepted Date 2022-02-11 16:21:25 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Santi Therapeutics, Inc. See All Filings	D	2021-09-17 16:21:02 UTC
Amount To Be Raised $10,000,000 Associated Brokers / Dealers N/A CIK Number 0001815337 Filed Document 0001815337-21-000001 Exclusions or Exemptions 506b Accepted Date 2021-09-17 16:21:02 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity
Santi Therapeutics, Inc. See All Filings	D	2020-07-06 17:10:57 UTC
Amount To Be Raised $14,000,000 Associated Brokers / Dealers N/A CIK Number 0001815337 Filed Document 0001815337-20-000001 Exclusions or Exemptions 506b Accepted Date 2020-07-06 17:10:57 UTC Type of Offering D Industry Pharmaceuticals Principal Place of Business MASSACHUSETTS Revenue or Assets Decline to Disclose Type of Security Equity